Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for HAART-Associated Bone Loss in HIV
NCT01228318Phase 2Completed
- Sponsor
- Emory University
- Start
- Jan 2011
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis and osteopenia comparing Zoledronic acid with Placebo (2 arms). Primary endpoints: C-terminal Telopeptide of Collagen at 144 weeks, Bone Mineral Density at 24 weeks and 1 more. Started Jan 2011; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on NCT01228318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01228318.